Nivolumab and ipilimumab
Brand Name: Opdivo and Yervoy
Manufacturer: Bristol Myers Squibb
Indication
Indication
First-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
Specific CRC Subtype: MSI-H/dMMR
Stage: IV
Therapy Line: First-line
Health Canada Approval: Approved
pCPA Negotiation Status: Completed
Reimbursed in:
New Search
